SCHEMBL20124948

SCHEMBL20124948

Cc1ccc(F)cc1OCCO

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
TSHR P16473 2/20 0.44
ALDH1A1 P00352 1/20 0.41
MKNK2 Q9HBH9 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 2/20 0.40
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
HTR2B P41595 2/20 0.39
TTR P02766 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C8 P10632 1/20 0.39
CHRM1 P11229 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRA1A P35348 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078701 0.85 MRGPRX4 (0.48) ALDH1A1ALOX5APFEN1HTR2BHTR2C
SCHEMBL13069271 0.83 FFAR1 (0.47) FFAR1FFAR4TSHRALDH1A1TDP1
SCHEMBL2226476 0.82 HTR2C (0.44) FFAR1FFAR4ALDH1A1MKNK2TDP1
SCHEMBL25974302 0.81 FFAR1 (0.46) FFAR1FFAR4TSHRALDH1A1TDP1
SCHEMBL20224818 0.81 FFAR1 (0.46) FFAR1FFAR4TSHRTDP1LMNA
SCHEMBL2334724 0.81 ALOX5AP (0.44) TDP1ALOX5APFEN1CYP11B1CYP11B2
SCHEMBL516010 0.81 TSHR (0.64) TSHRALDH1A1TDP1LMNAHTR2B
SCHEMBL14015 0.80 FFAR1 (0.44) FFAR1FFAR4TSHRTDP1LMNA
SCHEMBL4311769 0.80 HTR2C (0.55) FFAR1FFAR4ALDH1A1TDP1HTR2B
SCHEMBL9631985 0.80 KCNH2 (0.54) FFAR1FFAR4ALDH1A1TDP1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303495-A9 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) 2023-09-28 US disclosed
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
US-20230026907-A1 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF ORION CORP (FI) 2023-01-26 US disclosed
EP-2970275-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026907-A1 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF SCN11A, HCN4, CACNA1F FFAR1 275/4885FFAR4 262/4885TSHR 3349/4885
US-20230303495-A9 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF SCN11A, HCN4, CACNA1F FFAR1 275/4885FFAR4 262/4885TSHR 3349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.